you are all missing the point- this had little to do with AW or anyone else- its all about the consultants- they were working with MW to see what it would take to make AAH a significant portion of the overall Abbott organization- when they learned how much $$ and people and time it would take, MW decided it wasn't worth it for the organization, - how convenient that the same consultant was working with Zoetis to reorganize to avoid the hostile takeover bid by Ackerman- the purchase of AAH was less an investment in Z's future than it was a defensive move by Zoetis. Reduced their cash on hand, increased the complexity of their organization, and makes it harder for Ackerman.
the industry's future? Look at Idexx- going direct - there will be less reliance by manufactures on distribution- they will sell the highly profitable marquee products (with DTC advertising- eg Rimadyl) direct to maintain control and margin, and leave all the 'me too' low margin products with human generic equivalents (like the entire AAH portfolio) to the distributors to deal with. The HS reps I talked to all lost 33% of their income with that deal- and now that all 3 major vet distributors are backed by 3 large human healthcare distributors, and product can be ordered via internet, the future looks pretty bleak for DSRs as well, I think.
All the inappropriate attacks and general meanness here are totally unnecessary and uncalled for. We are all just pawns in a very large chess game, and individually have little impact on the ultimate outcome. if that hurts your pride, I am sorry, but that is the truth- If I were Miles, I would probably have made the same decision.
Be thankful you were part of one of the best organizations in the world (yes, in spite of what you think about AAH, Abbott Labs is just that), and no one can take that off your resume- or what you learned about the industry while you were here.